Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.

J Med Chem

Roche Innovation Center Shanghai, ‡Roche Innovation Center Basel, §Medicinal Chemistry, ∥Chemical Biology, ⊥Pharmaceutical Sciences, #Discovery Virology, Roche Pharma Research and Early Development , Bldg 5, 720 Cailun Road, Shanghai 201203, China.

Published: April 2017

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.7b00083DOI Listing

Publication Analysis

Top Keywords

4-h haps
12
third-generation 4-h
8
hbv capsid
8
capsid inhibitors
8
carboxyl group
8
4-h
5
discovery pre-clinical
4
pre-clinical characterization
4
characterization third-generation
4
4-h heteroaryldihydropyrimidine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!